Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids

[1]  W. Kannel,et al.  Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. , 2020, Annals of internal medicine.

[2]  H. Mabuchi.  Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases , 2004 .

[3]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[4]  J. Cuzick,et al.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[6]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[8]  C. Viscoli,et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke. , 2001, The New England journal of medicine.

[9]  V. Kataja,et al.  Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Holli,et al.  Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer , 2000, Breast Cancer Research and Treatment.

[11]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[12]  E. Vittinghoff,et al.  Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. , 2000, JAMA.

[13]  D. Hayes,et al.  Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer , 1999, Breast Cancer Research and Treatment.

[14]  G. Liu,et al.  Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. , 1998, Biochemical and biophysical research communications.

[15]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[16]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[17]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[18]  P. Hietanen,et al.  Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  N. Wintfeld,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[20]  R. Rosenson,et al.  Lipoprotein Lp(a) excess and coronary heart disease. , 1997, Archives of internal medicine.

[21]  M. Taskinen,et al.  Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Feyzi,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.

[23]  S. Grundy,et al.  Hypercholesterolemia in postmenopausal women: Metabolic defects and response to low‐dose lovastatin , 1994, JAMA.

[24]  L. Rutqvist,et al.  Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[25]  R. Krauss,et al.  Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. , 1992, Atherosclerosis.

[26]  P. Lesnik,et al.  Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. , 1991, Journal of lipid research.

[27]  C. McDonald,et al.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.

[28]  E. Boerwinkle,et al.  Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. , 1990, The New England journal of medicine.

[29]  Y. Matsuzawa,et al.  [Recent trend in the research of hyperlipidemia in Japan (1). Profiles of primary hyperlipidemia]. , 1989, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[30]  M. King,et al.  Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. , 1988, American journal of human genetics.

[31]  L. Kuller,et al.  SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MEN , 1986, The Lancet.

[32]  M. Perilä,et al.  A new triphenylethylene compound, Fc-1157a , 1986, Cancer Chemotherapy and Pharmacology.

[33]  H. Mouridsen,et al.  Tamoxifen in advanced breast cancer. , 1978, Cancer treatment reviews.

[34]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[35]  E. Kalkhoven,et al.  Isoforms of steroid receptor co‐activator 1 differ in their ability to potentiate transcription by the oestrogen receptor , 1998, The EMBO journal.

[36]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .